Karina Dahl Steffensen

Summary

Affiliation: Odense University Hospital
Country: Denmark

Publications

  1. ncbi The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer
    K D Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Int J Gynecol Cancer 17:798-807. 2007
  2. ncbi Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer
    K D Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Int J Gynecol Cancer 18:702-10. 2008
  3. ncbi Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Clin Cancer Res 14:3278-82. 2008
  4. ncbi Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, DK 7100 Vejle, Denmark
    Int J Oncol 33:195-204. 2008
  5. ncbi Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer
    Else Maae
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Anticancer Res 32:3619-27. 2012
  6. ncbi The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Kabbeltoft 25, Vejle, Denmark
    Int J Gynecol Cancer 22:1474-82. 2012
  7. ncbi The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Int J Gynecol Cancer 19:820-5. 2009
  8. ncbi Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Kabbeltoft 25, DK 7100 Vejle, Denmark
    BMC Cancer 10:185. 2010
  9. ncbi Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer
    Maja Patricia Smerdel
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Int J Gynecol Cancer 19:578-84. 2009
  10. ncbi Serum platelet-derived growth factor and fibroblast growth factor in patients with benign and malignant ovarian tumors
    Christine Vestergaard Madsen
    Departments of 1Oncology, Vejle Hospital, Vejle, Denmark
    Anticancer Res 32:3817-25. 2012

Collaborators

Detail Information

Publications19

  1. ncbi The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer
    K D Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Int J Gynecol Cancer 17:798-807. 2007
    ..Positive HER2 expression also notified a grave prognosis, but the low rate of overexpression reduces its potential clinical application...
  2. ncbi Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer
    K D Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Int J Gynecol Cancer 18:702-10. 2008
    ..In addition, the TT genotype seems to be favorable toward better response to platinum-based chemotherapy...
  3. ncbi Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Clin Cancer Res 14:3278-82. 2008
    ..EGFRvIII has not been found in normal tissue, and consequently, it is an attractive tumor-specific candidate for molecular targeted treatment. The literature dealing with this mutation in ovarian cancer has been very sparse...
  4. ncbi Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, DK 7100 Vejle, Denmark
    Int J Oncol 33:195-204. 2008
    ....
  5. ncbi Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer
    Else Maae
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Anticancer Res 32:3619-27. 2012
    ..We investigated the possible prognostic impact of VEGFA single nucleotide polymorphisms (SNPs) in patients with HER2-positive primary breast cancer...
  6. ncbi The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Kabbeltoft 25, Vejle, Denmark
    Int J Gynecol Cancer 22:1474-82. 2012
    ..Furthermore, we wanted to investigate the dynamics of the markers during treatment...
  7. ncbi The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Int J Gynecol Cancer 19:820-5. 2009
    ....
  8. ncbi Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Kabbeltoft 25, DK 7100 Vejle, Denmark
    BMC Cancer 10:185. 2010
    ....
  9. ncbi Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer
    Maja Patricia Smerdel
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Int J Gynecol Cancer 19:578-84. 2009
    ..The aim of the present study was to examine the possible importance of 2 VEGF polymorphisms and VEGF-A expression in ovarian cancer...
  10. ncbi Serum platelet-derived growth factor and fibroblast growth factor in patients with benign and malignant ovarian tumors
    Christine Vestergaard Madsen
    Departments of 1Oncology, Vejle Hospital, Vejle, Denmark
    Anticancer Res 32:3817-25. 2012
    ..The platelet-derived growth factor (PDGF) system and fibroblast growth factor (FGF) system are important components in tumor growth and angiogenesis...
  11. ncbi Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer
    Else Maae
    Department of Oncology, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark
    Breast Cancer Res Treat 133:257-65. 2012
    ..In conclusion, our results support the mutual relationship between PlGF and VEGF-A and encourage further investigations as prognostic markers in breast cancer patients...
  12. ncbi Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Int J Gynecol Cancer 21:1040-7. 2011
    ..The aim of the present study was to investigate the prognostic value of prechemotherapy serum HER2, cancer antigen 125 (CA125), and HE4 levels in ovarian cancer patients receiving standard combination chemotherapy...
  13. ncbi Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab
    Christine Vestergaard Madsen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    J Ovarian Res 5:23. 2012
    ..abstract:..
  14. ncbi Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Int J Gynecol Cancer 23:73-80. 2013
    ..The aim of this study was to investigate the response rate in platinum-resistant, KRAS wild-type ovarian cancer patients treated with pegylated liposomal doxorubicin (PLD) supplemented with panitumumab...
  15. ncbi Quantitative detection of HER2 protein concentration in breast cancer tissue does not increase the number of patients eligible for adjuvant HER2-targeted therapy
    Troels Bechmann
    The Faculty of Health Sciences, University of Southern Denmark, and Department of Pathology, Odense University Hospital, Odense, Denmark
    Oncol Rep 29:1475-82. 2013
    ..020). Quantitative HER2 determination by Centaur did not define a new group of patients eligible for HER2-targeted therapy. Currently, tissue HER2 status defined by IHC/FISH analysis remains the gold standard...
  16. ncbi Improved classification of epithelial ovarian cancer: results of 3 danish cohorts
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Int J Gynecol Cancer 21:1592-600. 2011
    ..In the present study, we performed a comprehensive study in a large Danish material to evaluate the clinical importance...
  17. ncbi The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab
    M P Smerdel
    Department of Oncology, Vejle Hospital, Kabbeltoft 25, Vejle, Denmark
    Gynecol Oncol 118:167-71. 2010
    ....
  18. ncbi The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer
    K D Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Gynecol Oncol 117:109-16. 2010
    ..Furthermore, we evaluated the functional significance of the SNPs as determined by the influence on serum VEGF levels in ovarian cancer...
  19. ncbi Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark
    J Oncol 2011:620523. 2011
    ..026). This study suggests that quantification of the number of EOC stem cells in the tumor can be used as a predictor of disease and could be applied for treatment selection in early-stage ovarian cancer...